# Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

> **NCT03074006** · PHASE1 · COMPLETED · sponsor: **MedPacto, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** TEW-7197

## Key facts

- **NCT ID:** NCT03074006
- **Lead sponsor:** MedPacto, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074006, "Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03074006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*